Health Blueprint

Back to Longevity News

News summary

Traded: Venture Capital 🦄 on Instagram: "Enveda, an AI-native biotechnology company, raised $311 million in Series E funding led by Catalio Capital Management, bringing its total capital raised since inception to more than $845 million. Founder and CEO Viswa Colluru said the funding will advance three clinical-stage medicines, including ENV-294 and ENV-308 into later-stage trials, expand the pipeline into inflammatory and metabolic conditions, and scale its PRISM AI drug-discovery platform. FOUNDER: Viswa Colluru, Ph.D INVESTORS: Catalio Capital Management, Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, T. Rowe Price Investment Management, Digitalis Ventures, Sovereign Wealth Fund, Alderline Group, Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital & Lux Capital ROUND: Series E AMOUNT: $311,000,000 HQ: Boulder, Colorado #VentureCapital #Enveda #ViswaColluruPhD #TradedVC"

Source: traderVC • Published: 23 Sept 2026, 19:13

Summarized by Masters of Longevity from traderVC.

Funding update on a biotech using AI for drug discovery, reporting a large Series E raise to advance clinical candidates and scale its platform.

Traded: Venture Capital 🦄 on Instagram: "Enveda, an AI-native biotechnology company, raised $311 million in Series E funding led by Catalio Capital Management, bringing its total capital raised since inception to more than $845 million. Founder and CEO Viswa Colluru said the funding will advance three clinical-stage medicines, including ENV-294 and ENV-308 into later-stage trials, expand the pipeline into inflammatory and metabolic conditions, and scale its PRISM AI drug-discovery platform. FOUNDER: Viswa Colluru, Ph.D INVESTORS: Catalio Capital Management, Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, T. Rowe Price Investment Management, Digitalis Ventures, Sovereign Wealth Fund, Alderline Group, Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital & Lux Capital ROUND: Series E AMOUNT: $311,000,000 HQ: Boulder, Colorado #VentureCapital #Enveda #ViswaColluruPhD #TradedVC"
Key Takeaways
  • The company raised $311 million in a Series E financing led by Catalio Capital Management.
  • Total capital raised by the company now exceeds $845 million since inception.
  • Proceeds will push three clinical-stage medicines toward later-stage trials and expand the AI drug-discovery platform.
Read the full article at traderVC ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.